Gary Goldman, Ph.D.

Gary S. Goldman holds a Ph.D. in Computer Science from Pacific Western University in Los Angeles and graduated with honors in 1977 from California State University, Fullerton (CSUF) with a double major: B.S. Engineering (Electronic emphasis) and B.S. Computer Science. He was elected member of the Phi-Kappa-Phi honor society and in 1976 received the Outstanding University Engineering Student Award, presented by the Orange County Engineering Education Council (OCEC). At graduation he received a special Merit Award in recognition of scholarly commitment and outstanding Academic Achievement in Computer Science, presented by CSUF.

At CSUF, Goldman was employed as a computer consultant assisting faculty and staff. He later served as a part-time assistant professor for the Engineering and Quantitative Methods departments instructing both graduate and undergraduate courses in statistics, programming, digital simulation, and digital logic design and switching theory.

In 1980, as vice-president of Systems Development of Cascade Graphics Development, he developed the first microcomputer-based computer-aided drafting (CAD) system (prior to the well known AutoCad product; see figure). This system used an Apple II to process user inputs and a 68000 microprocessor to perform real time graphics. Dr. Gilbert McCann, then professor emeritus of CalTech, served on the board of directors of this company. Goldman engaged in computer consulting tours to South Africa, Germany, Holland, England and Canada. Goldman holds a U.S. patent (#4223255, granted September, 1980) for a micro-programmed, high-efficiency motor-in-a-wheel called “Power Wheel,” for use in electric vehicular applications. This invention was featured on the front cover of the Fall, 1980 issue of Science and Mechanics (see figure).

After operating one year independently, Cascade Graphics Development was acquired by an international petrochemical company. In the early 1980’s, Dr. Goldman assisted with the integration of the graphics system and voice input Technology. This product, unique for its time, permitted disabled persons to be productive and generate high quality drawings. He recalls hiring a quadriplegic who accomplished fulfilling and productive work on this system. Dr. Goldman automated the design of vertical cylindrical heaters, including convection coil design and tube-wall thickness calculations for the piping. Dr. Goldman wrote a heuristic program that designed earth retaining walls with and without traffic loads and provided the complete materials list and drawing for the project. Goldman’s program could produce a 100-foot long wall along any given terrain in five minutes—a task that previously took several engineers an entire week to accomplish. He also developed a specialized curve fitting routine, used by pilot Burt Rutan, suitable for aircraft wing design.

He co-developed the Goldman/Blake remediation program for children with specific visual process deficits; this program was used in a pilot study at the Hope-Haven Hospital in Florida. In 1976, he served on a development team that produced the first Interactive Graphics Terminal, IGT-100, at CalComp (California Computer Products, Anaheim, CA) This system allowed drawings to be edited prior to their being electronically plotted.

For 30 plus years, Goldman has served as a computer consultant responsible for the automation of a wide variety of businesses, improved production, and conversion of databases. He has authored and presented numerous manuscripts contributing to engineering and computer science disciplines and enjoys writing heuristic programs (developing algorithms based on ones knowledge and intuition concerning a problem).

Dr. Goldman served for eight years (from January, 1995 until his resignation in October of 2002) as Research Analyst for the Varicella Active Surveillance Project (VASP) in Antelope Valley, in a cooperative project with the Centers for Disease Control and Prevention (CDC, Atlanta, GA). He developed a model that quantified the seasonal variation in chickenpox based on school enrollment (clustering) and high ambient air temperature. Additionally, he created a database and data entry programs for several hundred demographic and clinical variables pertaining to chickenpox and shingles. This included logic to detect case duplicates (important for application of capture-recapture methods) and link cases originating from the same household. He also supplied the initiative and background material for the proposal to add shingles to the active surveillance program. Additionally, he wrote statistical analyses to (a) investigate 2nd varicella infections (later published in peer-reviewed medical journal), (b) study varicella susceptibility (presented at a symposium and published later outside VASP), (c) quantify transmission of varicella in households, (d) determine chickenpox vaccine efficacy by year (published later outside VASP), (e) track outbreaks of chickenpox in schools, (f) perform a cost-benefit analysis of universal varicella vaccination taking into account the closely related herpes zoster epidemiology (published later outside VASP), and (g) perform capture-recapture to measure reporting completeness of chickenpox cases to the surveillance project (published in The Journal of the American Medical Association–JAMA). Finally, Goldman computed both (1) true shingles incidence rate among children with previous histories of chickenpox and (2) true shingles incidence rate among vaccinated children so as to investigate trends in shingles incidence in a community under moderate to widespread varicella vaccination (published later outside VASP).

Presently, Dr. Goldman serves as a consulting computer scientist and is on the board of directors of Pearblossom Private School, Inc. which provides distance education to over 1,500 independent study students each year in grades K through 12 throughout the United States (see www.PearblossomSchool.com).

From 2004 through 2010 he served as Editor-in-Chief of the peer-reviewed journal, Medical Veritas: The Journal of Medical Truth (see www.MedicalVeritas.com). Through this endeavor Dr. Goldman has had the pleasure of interfacing with world-renowned scientists, researchers, and physicians.

Dr. Goldman has served as a reviewer for the Journal of the American Medical Association (JAMA), Human and Experimental Toxicology (HET), Vaccine, The American Journal of Managed Care (AJMC), Expert Review of Vaccines (ERV), Expert Review of Dermatology (ERD), Journal of the European Academy of Dermatology and Venereology (JEADV), Epidemiology and Infection, The Open Allergy Journal, BioMed Research International (Biomed Res Int), and British Medical Journal (BMJ). He is included on the Editorial Board of Research and Reviews in BioSciences.

Gary Goldman, PhD
Gary S. Goldman, Vice-President Cascade Graphics Development
Patented "Power Wheel"
Goldman, V.P. Cascade Graphics Dev., with First CAD System in 1980.

“In 1995 I was hired as an Epidemiology Analyst on the Antelope Valley Varicella Active Surveillance Project–a joint project of the Los Angeles County Department of Health Services (LACDHS)–Acute Communicable Disease Control Unit and the Centers for Disease Control and Prevention (CDC, Atlanta, GA). Initially, I considered it an honor to be part of a team that was to study the effect of the varicella vaccine on the 300,000 residents comprising the Antelope Valley region. While all positive effects of the vaccine were readily approved for publication, it appeared the deleterious effects (e.g., increases in shingles incidence among unvaccinated children and adults that had natural varicella) were being suppressed.  After 8 years, I resigned from my employment so as to publish all the results and not be a party to what I perceived as research fraud–with the sponsors of the research seemingly squashing objective research and dictating published outcomes. I was served a notice to “cease and desist” publication of the results in a medical journal, but overcame that objection and the studies were indeed published. Both the LACDHS and CDC continued (unsuccessfully) to interfere and attempt to prevent publication of manuscripts after they had already been accepted and approved for publication by various medical journal editors. Intervention of my attorney was necessary in some cases.” – Gary Goldman, Ph.D.

Publications
[1] Assessing the Impact of Vaccination on the Incidence of Vaccine Preventable Diseases via Harmonic Regression. Presented May 23, 2000 by John W. Glasser (CDC). GS Goldman, JW Glasser, TJ Maupin, CL Peterson, . Mascola, RT Chen, and JF Seward.

[2] The impact of vaccination on varicella incidence, conditional on school attendance and temperature, in Antelope Valley, CA. Goldman GS, Glasser JW, Maupin TJ, Peterson CL, Mascola L, Chen RT, and Seward JF. Presentation by J.W. Glasser at 16th International Conference on Pharmacoepidemiology (ICPE); Barcelona, Spain; August 22, 2000; Pharmacoepidemiology and Drug Safety; 9(Suppl 1):S67.

[3] Varicella active surveillance: use of capture-recapture methods to assess completion of surveillance data. Peterson CL, Maupin T, Goldman G, Mascola L. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 28 – October 1, 1997, Toronto, Canada; Abstract H-111, page 233.

[4] Decline in varicella incidence and hospitalizations in sentinel surveillance areas in the United States, 1995-2000. Seward J, Watson B, Peterson C, Mascola L, Pelosi J, Zhang J, Jumaan A, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M. The 4th International Conference on VZV, March 3-5, 2001, Oral Presentation, La Jolla, California. VZV Research Foundation in partnership with Columbia University College of Physicians and Surgeons.

[5] Breakthrough varicella cases since vaccine licensure in the Varicella Active Surveillance Project. April 2001 Supplement of Pediatric Research, Presented April 28-May 1, 2001 Pediatric Academic Societies Meeting, Baltimore, Maryland. Galil K, Watson B, Peterson C, Mascola L, Pelosi J, Seward J, Zhang J, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M. Centers for Disease Control and Prevention, Atlanta, GA; Philadelphia Department of Public Health, Philadelphia, PA; Los Angeles County Department of Health, Los Angeles, CA; Texas Department of Health, Austin, TX; Dyntel Corporation, Atlanta, GA. Publication no. 843.

[6] Knowledge, attitudes, and practices of healthcare providers regarding varicella vaccination in sentinel surveillance area, 1996, 1997, and 1999. Maupin T, Goldman G, Peterson C, Mascola L, Seward J. Poster Session, April 28-May 1 2001, Pediatric Academic Society Annual Meeting, Baltimore, Maryland.

[7] Varicella Epidemiology: six years of active surveillance data following implementation of the varicella vaccination program. Peterson C, Mascola L, Maupin T, Goldman G, Seward J, Presented at the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 943, October 25-28, 2001; San Francisco, California.

[8] Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Xhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. JAMA 2002; 287(5):606–11.

[9] Second varicella infections: are they more common than previously thought? Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Pediatrics. 2002 Jun;109(6):1068–73.

[10] Varicella susceptibility among adolescents in an active surveillance site. Maupin T, Goldman G, Peterson C, Mascola L, Seward J, Jumaan A, 36th National Immunization Conf. of the CDC, 05/01/02, Denver, CO.

[11] Varicella susceptibility and incidence of herpes-zoster among children and adolescents in a community under active surveillance. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4238–42.

[12] Incidence of herpes-zoster among children and adolescents in a community with moderate varicella vaccination coverage. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4243–9.

[13] Using capture-recapture methods to assess varicella incidence in a community under active surveillance. Goldman G. Vaccine, 2003 Oct 1; 21(27-30):4250–55.

[14] Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Goldman G. Vaccine, 2005 May; 23(25):3349–55.

[15] An investigation of the association between MMR vaccination and autism in Denmark. Goldman G, Yazbak EF, Journal of Association of American Physicians and Surgeons, Fall 2004; 9(3):70–5.

[16] Response to Letter to Editor by Jumaan: Goldman’s role in the Varicella Active Surveillance Project. Goldman GS. Vaccine, 2004 Sep 3; 22(25-26):3232–6. (doi:10.1016/j.vaccine.2004.07.001)

[17] Annual Summary, Each year 1995 through 2001, Antelope Valley Varicella Active Surveillance Project (VASP), Los Angeles County Department of Health Services (LACDHS); Centers for Disease Control and Prevention (CDC) Cooperative Agreement No. U66/CCU911165-10; Maupin T, Goldman G, Peterson C, Mascola L.

[18] Universal varicella vaccination: Efficacy trends and effect on herpes-zoster. Goldman GS. International Journal of Toxicology, 2005 July-Aug.;24(4):205–13.

[19] The Case against Universal Varicella Vaccination. [Commentary] Goldman GS. International Journal of Toxicology, 2006 Sept.-Oct.,25(5):313–17.

[20] Infant mortality rates regressed against number of vaccine doses routinely given: Is there a biochemical or synergistic toxicity? Miller NZ, Goldman GS. Hum Exp Toxicol., 2011 Sept.; 30(9):1420-8. (Sage Open Access article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170075/pdf/10.1177_0960327111407644.pdf)

[21] Relative trends in hospitalizations and mortality among infants by number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Goldman GS, Miller NZ. Hum Exp Toxicol 2012 Oct; 31(10):1012-21.

[22] Comparison of VAERS fetal-loss reports during three consecutive influenza seasons: Was there a synergistic fetal toxicity associated with the two-vaccine 2009/10 season? Goldman GS. Hum Exp Toxicol 2012 Oct;31(10):1012-21.

[23] Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy primarily based primarily on the Antelope Valley Varicella Active Surveillance Project data. Goldman GS, King PG. Vaccine 2012;31(13):1680-94; http://dx.doi.org/10.1016/j.vaccine.2012.05.050

[24] Vaccination to prevent varicella: Goldman and King’s response to Myers’ interpretation of Varicella Active Surveillance Project data. Goldman GS, King P. Hum Exp Toxicol, 2013, Dec 10; PMID: 24275643.